z-logo
open-access-imgOpen Access
Chain-Terminating Dinucleoside Tetraphosphates Are Substrates for DNA Polymerization by Human Immunodeficiency Virus Type 1 Reverse Transcriptase with Increased Activity against Thymidine Analogue-Resistant Mutants
Author(s) -
Peter R. Meyer,
Anthony J. Smith,
S. Matsuura,
Walter A. Scott
Publication year - 2006
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00537-06
Subject(s) - reverse transcriptase , dna , primer (cosmetics) , thymidine , mutant , biology , dna synthesis , microbiology and biotechnology , nucleotide , nucleotidyltransferase , mutation , biochemistry , chemistry , rna , gene , organic chemistry
Nucleoside reverse transcriptase inhibitors are an important class of drugs for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Resistance to these drugs is often the result of mutations that increase the transfer of chain-terminating nucleotides from blocked DNA termini to a nucleoside triphosphate acceptor, resulting in the generation of an unblocked DNA chain and synthesis of a dinucleoside polyphosphate containing the chain-terminating deoxynucleoside triphosphate analogue. We have synthesized and purified several dinucleoside tetraphosphates (ddAp4 ddA, ddCp4 ddC, ddGp4 ddG, ddTp4 ddT, Ap4 ddG, 2′(3′)-O -(N -methylanthraniloyl)-Ap4 ddG, and AppNHppddG) and show that these compounds can serve as substrates for DNA chain elongation and termination resulting in inhibition of DNA synthesis. Thymidine analogue-resistant mutants of reverse transcriptase are up to 120-fold more sensitive to inhibition by these compounds than is wild-type enzyme. Drugs based on the dinucleoside tetraphosphate structure could delay or prevent the emergence of mutants with enhanced primer unblocking activity. In addition, such drugs could suppress the resistance phenotype of mutant HIV-1 that is present in individuals infected with resistant virus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here